Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | RPA1 | P27694 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31212211 | 1.00 | BCL2L1 (0.53) | BCL2L1BADNR4A2CSNK2A2CSNK2B | |
| SCHEMBL31212281 | 0.86 | NPC1 (0.45) | BCL2L1BADNR4A2CSNK2A2CSNK2B | |
| SCHEMBL25982626 | 0.86 | NPC1 (0.45) | BCL2L1BADNR4A2CSNK2A2CSNK2B | |
| SCHEMBL31025344 | 0.85 | SMN1; SMN2 (0.58) | CSNK2A2CSNK2BDHODHNPC1ALDH1A1 | |
| SCHEMBL4124819 | 0.85 | SMN1; SMN2 (0.58) | CSNK2A2CSNK2BDHODHNPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL400411 | 0.84 | SMN1; SMN2 (0.57) | CSNK2A2CSNK2BDHODHNPC1ALDH1A1 | |
| SCHEMBL27077491 | 0.84 | CYP2C8 (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL25982802 | 0.84 | KMO (0.55) | CSNK2A2CSNK2BDHODHNPC1ALDH1A1 | |
| SCHEMBL31212385 | 0.84 | KMO (0.55) | CSNK2A2CSNK2BDHODHNPC1ALDH1A1 | |
| SCHEMBL17941969 | 0.82 | NPC1 (0.57) | NPC1RXFP1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150663-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| EP-3247705-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | NAMPT, NQO2, NNMT | BCL2L1 4376/4885BAD 2341/4885NR4A2 302/4885 |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | BCL2L1 4376/4885BAD 2341/4885NR4A2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.